By Robert Barba

Amgen INc. reported better-than-expected third quarter results, as demand for its products were partially offset by lower net selling prices.

The pharmaceutical company reported revenue of $6.7 billion, up from $6.42 billion a year earlier. Revenue was ahead of analysts' expectations of $6.67 billion, according to FactSet.

Amgen said it saw double-digit volume growth in a number of its products. It also said revenue was affected by lower net selling prices.

Expenses were $4.32 billion, up from $3.97 billion a year earlier, as the company's research and development expenses in the quarter rose primarily because of a licensing-related expense from its collaboration with Kyowa Kirin.

Net income was $1.88 billion, down from $2.02 billion. Earnings per share were $3.31, down from $3.43 a year earlier.

Adjusted earnings were $4.67 a share. Analysts were expecting adjusted earnings of $4.28 a share.

Write to Robert Barba at robert.barba@wsj.com

(END) Dow Jones Newswires

11-02-21 1639ET